Analyzing Cytori Therapeutics (CYTX) and Its Peers
Cytori Therapeutics (NASDAQ: CYTX) is one of 84 public companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it weigh in compared to its rivals? We will compare Cytori Therapeutics to similar businesses based on the strength of its valuation, profitability, earnings, analyst recommendations, institutional ownership, dividends and risk.
Risk & Volatility
Cytori Therapeutics has a beta of 2.79, indicating that its stock price is 179% more volatile than the S&P 500. Comparatively, Cytori Therapeutics’ rivals have a beta of 1.02, indicating that their average stock price is 2% more volatile than the S&P 500.
Earnings & Valuation
This table compares Cytori Therapeutics and its rivals gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Cytori Therapeutics||$8.75 million||-$17.75 million||-0.40|
|Cytori Therapeutics Competitors||$827.23 million||$159.50 million||72.35|
Cytori Therapeutics’ rivals have higher revenue and earnings than Cytori Therapeutics. Cytori Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent recommendations for Cytori Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cytori Therapeutics Competitors||181||1152||2516||90||2.64|
Cytori Therapeutics currently has a consensus price target of $3.65, suggesting a potential upside of 801.23%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 7.72%. Given Cytori Therapeutics’ higher probable upside, equities research analysts plainly believe Cytori Therapeutics is more favorable than its rivals.
Insider & Institutional Ownership
11.8% of Cytori Therapeutics shares are held by institutional investors. Comparatively, 66.9% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by institutional investors. 1.9% of Cytori Therapeutics shares are held by insiders. Comparatively, 11.5% of shares of all “Medical Equipment, Supplies & Distribution” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This table compares Cytori Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cytori Therapeutics Competitors||-127.08%||-20.20%||-8.99%|
Cytori Therapeutics rivals beat Cytori Therapeutics on 10 of the 12 factors compared.
Cytori Therapeutics Company Profile
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.